25345-77-1

Upstream product

• 831-82-3 4-Phenoxyphenol 
• 106-95-6 allyl bromide 
• 25345-76-0 1-phenoxy-4-allyloxybenzene 
• 459-57-4 4-fluorobenzaldehyde 
• 205382-04-3 1-phenoxy-(4-propenyloxy)benzene 
• 108-95-2 phenol 
• 67-36-7 4-phenoxy benzaldehyde 

Downstream Products

• 194792-58-0 2-propyl-4-phenoxyphenol 
• 1026360-23-5 {5-[3-(4-phenoxy-2-propyl-phenoxy)-propoxy]-indan-1-yl}-acetic acid ethyl ester 
• 314752-76-6 C₁₅H₁₆O₃ 
• 606966-62-5 hydroxy-{3-[4-(4-phenoxy-2-propyl-phenoxy)-butoxy]-phenyl}-acetic acid methyl ester 
• 228578-00-5 methyl 3-(3-(2-propyl-4-phenoxyphenoxy)propoxy)-mandelate 

Relevant academic research and scientific papers

Green Organocatalytic Synthesis of Dihydrobenzofurans by Oxidation-Cyclization of Allylphenols

A green and cheap protocol for the synthesis of dihydrobenzofurans via an organocatalytic oxidation of o -allylphenols is presented. The use of 2,2,2-trifluoroacetophenone and H 2 O 2 as the oxidation system, leads to a highly useful synthetic method, where a variety of substituted o -allylphenols were cyclized in high yields..

Selenium-containing analogues of WC-9 are extremely potent inhibitors of Trypanosoma cruzi proliferation

The obligate intracellular parasite, Trypanosoma cruzi is the etiologic agent of Chagas disease or American trypanosomiasis, which is the most prevalent parasitic disease in the Americas. The present chemotherapy to control this illness is still deficient

Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR α/γ/δ pan agonists: Synthesis, structure-activity relationship, and in vivo efficacy

Compounds that simultaneously activate the three peroxisome proliferator-activated receptor (PPAR) subtypes alpha, gamma, and delta hold potential to address the adverse metabolic and cardiovascular conditions associated with diabetes and the metabolic sy

ARYLTHIAZOLIDINEDIONE DERIVATIVES

Substituted 5-aryl-2,4-thiazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR alpha , delta and/or gamma mediated diseases, disorders and conditions.

5-Aryl thiazolidine-2,4-diones: Discovery of PPAR dual α/γ agonists as antidiabetic agents

A novel series of 5-aryl thiazolidine-2,4-diones based dual PPARα/γ agonists was identified. A number of highly potent and orally bioavailable analogues were synthesized. Efficacy study results of some of these analogues in the db/db mice model of type 2 diabetes showed them superior to rosiglitazone in correcting hyperglycemia and hypertriglyceridemia.

Arylthiazolidinedione and aryloxazolidinedione derivatives

Substituted 5-aryl-2,4-thiazolidinediones or 5-aryl-2,4-oxazolidinediones that also carry a second substituent in the 5-position of the heterocyclic ring are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR α, δ and/or γ mediated diseases, disorders and conditions.

Antidiabetic agents

The instant invention is concerned with aryl and heteroaryl oxyacetic acid type compounds which are useful antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and related diseases and for lowering triglyceride levels are also disclosed.

Arylthiazolidinedione derivatives

Substituted 5-aryl-2,4-thiazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR α, δ and/or γ mediated diseases, disorders and conditions.